Search

Your search keyword '"Bruse S"' showing total 618 results

Search Constraints

Start Over You searched for: Author "Bruse S" Remove constraint Author: "Bruse S"
618 results on '"Bruse S"'

Search Results

1. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

2. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

3. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

6. Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie

7. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

9. KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer

10. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

12. Reference standards for gene fusion molecular assays on cytological samples: an international validation study

14. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential

17. EP08.02-031 NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC

18. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

19. 572P High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer

20. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

21. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

22. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

24. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

25. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

26. The biological effect of small-scale ROS1 aberrations: An in silico analysis

27. Small-scale ROS1 aberrations: Functional impact and therapeutic potential

28. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM)

29. High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer

30. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)

31. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

32. Internal Fixation of Fresh Fractures

34. 758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer

35. Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung.

36. Concordance between multiple HRD assays is substantial in high-grade ovarian cancer

37. Homologous recombination repair deficiency as a predictive biomarker Basic mechanisms and detection methods

38. Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer

Catalog

Books, media, physical & digital resources